Loxo@Lilly

Loxo@Lilly company information, Employees & Contact Information

Explore related pages

Related company profiles:

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain. When you engage with Loxo@Lilly on LinkedIn (and any other of Lilly's social media channels), you are agreeing to these Community Guidelines in addition to the Terms and Conditions or other legal notices provided by Lilly and those of LinkedIn: https://e.lilly/guidelines

Company Details

Employees
310
Address
281 Tresser Blvd, 9th Floor,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Stamford, CT
Looking for a particular Loxo@Lilly employee's phone or email?

Loxo@lilly Questions

News

Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire

Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics PR Newswire

Kinetic and Mechanistic Studies of Human Oligoadenylate Synthetase 1 | Biochemistry - ACS Publications

Kinetic and Mechanistic Studies of Human Oligoadenylate Synthetase 1 | Biochemistry ACS Publications

Metro Moves: Loxo Oncology opens Louisville lab - Denver Gazette

Metro Moves: Loxo Oncology opens Louisville lab Denver Gazette

Loxo Oncology Announces Global Development and - GlobeNewswire

Loxo Oncology Announces Global Development and GlobeNewswire

Eli Lilly to buy Loxo Oncology for about $8 billion in cancer drug bet - CNBC

Eli Lilly to buy Loxo Oncology for about $8 billion in cancer drug bet CNBC

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics - statnews.com

Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics statnews.com

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting PR Newswire

A doctor’s perspective on blood cancer - KevinMD.com

A doctor’s perspective on blood cancer KevinMD.com

Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout - Fierce Pharma

Eli Lilly grabs spotlight at J.P. Morgan with $8B Loxo Oncology buyout Fierce Pharma

ASH 2020: Results From the Phase 1/2 BRUIN Trial - Cure Today

ASH 2020: Results From the Phase 1/2 BRUIN Trial Cure Today

Switchable Regioselective 6- endo or 5- exo Radical Cyclization via Photoredox Catalysis - ACS Publications

Switchable Regioselective 6- endo or 5- exo Radical Cyclization via Photoredox Catalysis ACS Publications

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting PR Newswire

Mablink Bioscience Enters an Agreement to be Acquired by Lilly - GlobeNewswire

Mablink Bioscience Enters an Agreement to be Acquired by Lilly GlobeNewswire

Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting PR Newswire

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet - PR Newswire

Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet PR Newswire

Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at the 2020 American Society of Hematology (ASH) Annual Meeting PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting - PR Newswire

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Mantle Cell Lymphoma and Non-Hodgkin Lymphomas at the American Society of Hematology (ASH) Annual Meeting PR Newswire

Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer - PR Newswire

Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer PR Newswire

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting - PR Newswire

Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting PR Newswire

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) - PR Newswire

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) PR Newswire

Top Loxo@Lilly Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant